RESUMO
BACKGROUND: Venous thromboembolism is common in patients with solid malignancies and brain metastases. Whether to anticoagulate such patients is controversial given the possibility of intracerebral haemorrhage (ICH). We evaluated the added risk of ICH in patients with brain metastases receiving therapeutic anticoagulation. METHODS: We performed a matched, retrospective cohort study of 291 patients (100 receiving therapeutic anticoagulation vs 191 controls) with brain metastases managed at Brigham and Women's Hospital/Dana-Farber Cancer Institute between 1998 and 2015. For each patient, all MRI studies of the brain were reviewed to identify ICH. Propensity score matching and multivariable Cox regression were used to mitigate confounding. RESULTS: The risk of ICH was comparable in patients receiving anticoagulation versus controls preanticoagulation. Postanticoagulation, we observed significant or borderline-significant associations between anticoagulation and development of any ICH (HR 1.31, 95% CI 0.96 to 1.79, p=0.09), ICH as identified by gradient echo/susceptibility-weighted imaging (HR 1.46, 95% CI 1.06 to 2.01, p=0.02), symptomatic ICH (HR 1.80, 95% CI 1.01 to 3.22, p=0.05), extralesional ICH (HR 5.82, 95% CI 1.56 to 21.7, p=0.009) and fatal ICH (HR 5.68, 95% CI 0.60 to 54.2, p=0.13). Anticoagulation was associated with differentially higher ICH risk in patients with prior ICH versus no prior ICH (HR 2.20 vs 0.68, respectively, p interaction <0.001) and symptomatic ICH risk in melanoma versus other primary malignancies (HR 6.46 vs 1.36, respectively, p interaction=0.02). CONCLUSIONS: Anticoagulation is associated with clinically significant ICH in patients with brain metastases, especially those with melanoma or prior ICH. The indication for anticoagulation and risk of intracerebral bleeding should be considered on an individual basis among such patients.
RESUMO
BACKGROUND: Obtaining routine radiographs in the postanesthesia care unit (PACU) after primary uncomplicated partial knee arthroplasty (PKA) is a common practice with unclear utility. The objective of this study is to determine the rate at which immediate postoperative radiographs identify an actionable problem after primary uncomplicated PKA and to determine the potential cost savings associated with foregoing the routine acquisition of these radiographs. METHODS: This was a retrospective review that assessed a consecutive series of 1366 primary uncomplicated PKAs (including 873 unicondylar knee arthroplasties, 313 patellofemoral arthroplasties, and 180 bicompartmental knee arthroplasties) performed between January 2008 and March 2016. Patients were separated into 2 cohorts: (1) those who had PACU radiographs (n = 1184), and (2) those who did not (n = 182). Operative reports and clinical follow-up records at the initial postoperative visit were reviewed to determine whether patients underwent early reoperation based on radiographic findings. The direct cost of PACU radiographs was estimated to be $33.63 based on average global Medicare payments from our institution. RESULTS: The rate of reoperation because of radiographic findings in the PACU or at the first follow-up was 0% (95% confidence interval: 0.0%-0.027%). The estimated direct radiographic expenditure for our 1366 patient cohort was nearly $46,000. CONCLUSION: Routine immediate postoperative PACU radiographs after primary uncomplicated PKA have limited clinical utility. Therefore, delaying postoperative radiographs until the initial follow-up office visit would result in substantial cost-savings without compromising the quality of patient care.